Abstract: The present invention relates to a novel anti-HLA-A2 antibody, and to a chimeric antigen receptor comprising said HLA-A2 antibody. The present invention further relates to an immune cell expressing said chimeric receptor antigen, and to therapeutic uses thereof, in particular for treating or preventing graft rejection or GVHD.

Abstract: Disclosed embodiments include generating code from a database query and providing a framework to develop complex data structures and the functions that access those data structures outside of the generated code to access the complex data structures. These data structure functions can be precompiled in order to save compilation time at query runtime, and linked to the generated code in a way that the framework can still inline function calls and apply various optimizations on the linked code.

Abstract: The present invention relates to methods and pharmaceutical compositions for enhancing CD8+ T cell-dependent immune responses in subjects suffering from cancer. In particular, the present invention relates to a method of enhancing the CD8+ T cell-dependent immune response in a subject suffering from cancer comprising administering to the subject a therapeutically effective amount of an agent capable of increasing intra-tumoral ceramide content.

Abstract: The present invention relates to methods and pharmaceutical composition for the treatment of cancer. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen for cancer, the method comprising: administering a pharmaceutically effective amount of a TNF? blocking agent to a subject in combination with the immune checkpoint inhibitor.

Abstract: Immune checkpoint inhibitors (ICI) have revolutionized therapy for advanced cancer, however many patients still do not respond to treatment. However, the efficacy and effectiveness of these therapies varies greatly across individual patients and among different tumour types. A substantial unmet need is thus the development of biomarkers of response to ICI, in order to identify, before initiation of treatment, which patients are likely to experience a response to and clinical benefit from such treatments. Here, the inventors analyzed SPHK1 mRNA in tumor biopsies by in situ hybridization using the RNAscope technology in a cohort of 32 patients suffering from metastatic melanoma. They showed that elevated expression of SPHK1, encoding sphingosine kinase 1 (SK1), which produces the oncometabolite sphingosine-1-phosphate (S1P) is associated with a poor survival in metastatic melanoma patients treated with to the well-known immune-checkpoint inhibitor anti-PD-1 antibody.

Abstract: The present invention relates to methods and pharmaceutical composition for the treatment of cancer. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen for cancer, the method comprising: administering a pharmaceutically effective amount of a TNF? blocking agent to a subject in combination with the immune checkpoint inhibitor.

Abstract: The present invention relates to methods for enhancing the potency of the immune checkpoint inhibitors. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen, the method comprising administering a pharmaceutically effective amount of a SK1 inhibitor to a subject in combination with the immune checkpoint inhibitor.

Abstract: The present invention relates to methods for enhancing the potency of the immune checkpoint inhibitors. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen, the method comprising administering a pharmaceutically effective amount of a SK1 inhibitor to a subject in combination with the immune checkpoint inhibitor.

Abstract: Disclosed embodiments include generating code from a database query and providing a framework to develop complex data structures and the functions that access those data structures outside of the generated code to access the complex data structures. These data structure functions can be precompiled in order to save compilation time at query runtime, and linked to the generated code in a way that the framework can still inline function calls and apply various optimizations on the linked code.

Abstract: The invention provides a method of cutting out an opening in a flat cardboard blank (10, 12) that is for use in manufacturing a package, wherein a first portion (18) of the blank (10, 12) and an ejector tape (34) that face each other are pressed together between a presser tool (24) and an activation tool (26) that face each other so as to cause the ejector tape (34) to stick exclusively on the first portion (18) of the blank (10, 12). The invention also provides an ejector tape for such a method.

Abstract: The present invention relates to methods and pharmaceutical composition for the treatment of cancer. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen for cancer, the method comprising: administering a pharmaceutically effective amount of a TNF? blocking agent to a subject in combination with the immune checkpoint inhibitor.

Abstract: The present invention relates to methods for enhancing the potency of the immune checkpoint inhibitors. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen, the method comprising administering a pharmaceutically effective amount of a SK1 inhibitor to a subject in combination with the immune checkpoint inhibitor.

Abstract: The present invention relates to methods and pharmaceutical compositions for enhancing CD8+ T cell-dependent immune responses in subjects suffering from cancer. In particular, the present invention relates to a method of enhancing the CD8+ T cell-dependent immune response in a subject suffering from cancer comprising administering to the subject a therapeutically effective amount of an agent capable of increasing intra-tumoral ceramide content.

Abstract: Phenolic resin compositions.Phenolic resin compositions containing an additive consisting of at least 20% by weight of an alkaline or alkaline-earth metaborate relative to the toal weight of the additive.Applications to the manufacture of phenolic prepreg mats which are stable in storage.

Abstract: Phenolic resin compositions.Phenolic resin compositions containing an additive consisting of at least 20% by weight of an alkaline or alkaline-earth metaborate relative to the total weight of the additive.Applications to the manufacture of phenolic pre-preg mats which are stable in storage.

Abstract: Phenolic resin compositions.Phenolic resin compositions containing an additive consisting of at least 20% by weight of an alkaline or alkaline-earth metaborate relative to the total weight of the additive.Applications to the manufacture of phenolic prepreg mats which are stable in storage.

Abstract: Reinforced phenolic laminates are provided with a finishing coat of a butylated phenol-formaldehyde resin, thereby removing surface irregularities. The finishing coat can be mass-pigmented to the desired color, thereby obviating the necessity of any additional color-containing coatings.

Abstract: In a process for hardening phenol-formaldehyde resol resins, comprising conducting the hardening of the resins with an acidic solution of water and/or an organic solvent having dissolved therein an aromatic sulphonic acid and/or concentrated sulphuric acid, the improvement comprising the hardening in the presence of aniline added to the phenolic resin beforehand in a quantity of between about 0.5 and 2% relative to the weight of the phenolic resin whereby the pot life is extended and the cure time is satisfactory, the resultant products being especially useful as prepegs.

Abstract: A continuous process for manufacturing quick-setting phenolic foams is improved by using as the hardening agent a concentrated, substantially anhydrous solution of boron trioxide, and using as the blowing agent an organic liquid having a boiling point of 20.degree.-80.degree. C. Curing times are shortened and the resultant foam, having uniformly molecularly dispersed therein about 0.25-10.5% by weight of boron, calculated as boric anhydride, has substantially uniform cells, improved fire resistance characteristics and superior mechanical properties.

Abstract: There are obtained laminates of improved fire resistance comprising a substrate of reinforced phenolic resin, directly coated on at least one side thereof with a surface layer of a furan resin, and bonded to the outer surface of the furan resin a "gel-coat" of an unsaturated polyester resin, wherein the furan resin contains boron in sufficient amounts to impart an improved fire resistance to the laminates as compared to the fire resistance of the outer surface gel-coat. The boron is introduced as boric anhydride by use of a substantially anhydrous boric anhydride hardener solution to harden the furan resin.